Related Experiment Video
Updated: Sep 30, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
'Omic' and hypothesis-driven research in the molecular pharmacology of cancer
1Genomics & Bioinformatics Group, Laboratory of Molecular Pharmacology, US National Cancer Institute, Building 37 Room 5068, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA. jw4i@nih.gov
Abstract:
Given the layered, evolutionary complexity of biological systems, it will not be possible to understand them comprehensively on the basis of hypothesis-driven research alone. Likewise, it will not be possible to do so solely through 'omic' studies of genes, proteins and other molecules in aggregate. The two modes of research are complementary and synergistic. The twin complexities of cancer biology and drug discovery demand such synergy as a basis for the next generation of oncopharmacomic research.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...